Gene-editing
InterventionPreclinical3 papers4 findingsMeSH D000072669
Outcomes
4LDL cholesterol
downin humans1
1 study
LDL cholesterol
downin humans1
Gene-editing decreases LDL cholesterol in humans.
Reviewearly phase clinical evaluation
CRISPR therapy for dyslipidemia · Current opinion in lipidology · 18 Sep 2026
PCSK9
downin humans1
1 study
PCSK9
downin humans1
Gene-editing decreases PCSK9 in humans.
Reviewearly phase clinical evaluation
CRISPR therapy for dyslipidemia · Current opinion in lipidology · 18 Sep 2026
ANGPTL3
downin humans1
1 study
ANGPTL3
downin humans1
Gene-editing decreases ANGPTL3 in humans.
Reviewearly phase clinical evaluation
CRISPR therapy for dyslipidemia · Current opinion in lipidology · 18 Sep 2026
Double-strand DNA breaks
downin humans1
1 study
Double-strand DNA breaks
downin humans1
Gene-editing decreases double-strand DNA breaks in humans.
Review
Precision Genome Engineering in Human Disease: Expanding Therapeutic Roles of CRISPR Technologies · Nigerian medical journal : journal of the Nigeria Medical Association · 14 Sep 2026
Funding
National Eye InstituteUS$1.3mEuropean Research Council€1.5mNational Institute of Diabetes and Digestive and Kidney DiseasesUS$795.6k5 grants since 2022
From n=1 to many: Scaling-up gene editing for future heart therapies
European Research CouncilKlinikum der Technischen Universität München€1.5m2027–2031
Developing gene editing platforms for retinal degeneration.
National Eye InstituteOregon State UniversityUS$609k2022–2027
Gene Editing for Environmentally-Responsive, Immune-Evasive Stem Cell-Derived Islets
National Institute of Diabetes and Digestive and Kidney DiseasesUniv of Massachusetts Med Sch WorcesterUS$795.6k2026–2031
Development of potent and safe CRISPR tools for in vivo gene editing using directed evolution
National Institute of Biomedical Imaging and BioengineeringScripps Research Institute, theUS$230k2024–2027
Optimizing lipid nanoparticles for retinal gene editing in the NHP
National Eye InstituteLegacy Emanuel Hospital and Health CenterUS$689.3k2024–2029